Über uns

Absea Biotechnology GmbH is the Berlin-based Innovation Center of the global Absea Group. We develop comprehensive proteomic and interactomic solutions to understand the molecular basis of diseases and drug actions. In a single experiment, our mass spectrometry-based analysis platform can reveal the structures, localizations and interaction networks of proteins inside of highly complex biological systems such as intact human cells. This gives unparalleled insights into the systemic response to disease, unveils off-target and downstream effects of therapeutics, and highlights promising drug targets. Working with partners in academia, biotech and pharma, we strive to use this wealth of information to advance biomedicine.

The global Absea group is a transformative force in the protein technology industry established in 2020. Our global team of over 250 employees caters to the needs of academic sresearchers in all areas of life sciences as well as industry partners active in AI-driven protein design, diagnostics, and drug development. In addition to our Berlin site, we have Manufacturing Centers in China and a Commercialization Center in the Bay Area. We strive to become a long-term partner for the world's leading labs, companies and service providers.

Our cutting-edge platform for developing soluble proteins and monoclonal antibodies offers unparalleled throughput, enabling approximately 1000 new development projects per month. Our growing protein library currently comprises >13,000 soluble proteins covering two thirds of the human proteome. Through dynamic collaborations with leaders in the life sciences, especially in proteomics, we continue to broaden our portfolio by developing a proteome-wide library of heavy-isotope labeled protein standards. Complementary, our monoclonal antibodies and antibody-conjugates, validated across diverse applications, stand ready for widespread supply to the general market.